Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion-Reference-Cited by-同舟云学术

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion

Published:2023-10-09 Issue:10 Volume:12 Page:1521
ISSN:2079-6382
Container-title:Antibiotics
language:en
Short-container-title:Antibiotics

Author:

Marino Andrea¹²^ORCID,Campanella Edoardo³,Stracquadanio Stefano²^ORCID,Calvo Maddalena⁴^ORCID,Migliorisi Giuseppe⁴^ORCID,Nicolosi Alice²,Cosentino Federica⁵,Marletta Stefano⁶^ORCID,Spampinato Serena³,Prestifilippo Pamela⁷,Stefani Stefania²^ORCID,Cacopardo Bruno¹,Nunnari Giuseppe¹^ORCID

Affiliation:

1. Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy

2. Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy

3. Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy

4. U.O.C. Laboratory Analysis Unit, A.O.U. “Policlinico-Vittorio Emanuele”, Via S. Sofia 78, 95123 Catania, Italy

5. Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy

6. Department of Diagnostic and Public Health, Section of Pathology, University of Verona, 37124 Verona, Italy

7. Intensive Care Unit, ARNAS Garibaldi Hospital, 95122 Catania, Italy

Abstract

This comprehensive review examines the unique attributes, distinctions, and clinical implications of ceftazidime–avibactam (CAZ-AVI) and meropenem–vaborbactam (MEM-VAB) against difficult-to-treat Enterobacterales infections. Our manuscript explores these antibiotics’ pharmacokinetic and pharmacodynamic properties, antimicrobial activities, in vitro susceptibility testing, and clinical data. Moreover, it includes a meticulous examination of comparative clinical and microbiological studies, assessed and presented to provide clarity in making informed treatment choices for clinicians. Finally, we propose an expert opinion from a microbiological and a clinical point of view about their use in appropriate clinical settings. This is the first review aiming to provide healthcare professionals with valuable insights for making informed treatment decisions when combating carbapenem-resistant pathogens.

Funder

MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Link

https://www.mdpi.com/2079-6382/12/10/1521/pdf

Reference70 articles.

1. (2023, March 02). European Centre for Disease Prevention and Control Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2021.

2. Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia;Kalil;Lancet Infect. Dis.,2018

3. Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results from a Nationwide Study in Italy (ALARICO Network);Falcone;Clin. Infect. Dis.,2023

4. Naimi, T., Ringwald, P., Besser, R., Thompson, S., and Bell, D. (2023, March 02). Antimicrobial Resistance. Available online: https://www.who.int/health-topics/antimicrobial-resistance.

5. Gaibani, P., Giani, T., Bovo, F., Lombardo, D., Amadesi, S., Lazzarotto, T., Coppi, M., Rossolini, G.M., and Ambretti, S. (2022). Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics, 11.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments;Antibiotics;2023-11-12